TCGA-78-7150-01A-21R-2039-07
— · cohortA4
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortA4
- subtype
- cohortA4
- age_years
- 59
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PROTEIN_SECRETION+0.460
- OXIDATIVE_PHOSPHORYLATION+0.400
- CHOLESTEROL_HOMEOSTASIS+0.370
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.370
- GLYCOLYSIS+0.360
- MTORC1_SIGNALING+0.360
- TGF_BETA_SIGNALING+0.360
- ADIPOGENESIS+0.330
- G2M_CHECKPOINT+0.320
- UV_RESPONSE_DN+0.320
Top 10 suppressed
- ALLOGRAFT_REJECTION-0.320
- HEDGEHOG_SIGNALING-0.230
- INFLAMMATORY_RESPONSE-0.210
- P53_PATHWAY-0.210
- IL6_JAK_STAT3_SIGNALING-0.180
- INTERFERON_GAMMA_RESPONSE-0.140
- IL2_STAT5_SIGNALING-0.130
- WNT_BETA_CATENIN_SIGNALING-0.130
- KRAS_SIGNALING_UP-0.120
- APICAL_JUNCTION-0.090
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MNG544 | — | — | 0.818 |
| 2 | SRR12696742 | — | — | 0.789 |
| 3 | BSR_03_0022_A2_S92 | — | C | 0.789 |
| 4 | TCGA-39-5034-01A-01R-1443-07 | — | cohortA3 | 0.788 |
| 5 | TCGA-50-5072-01A-21R-1858-07 | — | cohortA4 | 0.785 |
| 6 | f34c57ee-92a6-4e3b-acde-7fd631c42f87 | — | — | 0.774 |
| 7 | MNG778 | — | — | 0.769 |
| 8 | SJEPD031129_D1.RNA-Seq | EPN | Posterior Fossa EPN | 0.767 |
| 9 | TCGA-73-4670-01A-01R-1206-07 | — | cohortA4 | 0.767 |
| 10 | MNG1206 | — | — | 0.759 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 35 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PROTEIN_SECRETION | 0.460 | Remibrutinib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.400 | Remibrutinib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.370 | Remibrutinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.370 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.360 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.360 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.360 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.330 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.320 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.320 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.310 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.300 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.300 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.290 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.280 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.260 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.260 | Idelalisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.250 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.240 | Inavolisib | — uncovered |
| HYPOXIA | 0.210 | Idelalisib | — uncovered |